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Abstract The glycine^alanine repeat (GAr) of the Epstein^
Barr virus nuclear antigen-1 is a cis-acting transferable element
that inhibits ubiquitin/proteasome-dependent proteolysis in vitro
and in vivo. We have here examined the e¡ect of a synthetic 20-
mer GAr oligopeptide on the degradation of iodinated or biotin
labeled lysozyme in a rabbit reticulocyte lysates in vitro assay.
Micromolar concentrations of the GA-20 peptide inhibited the
hydrolysis of lysozyme without signi¢cant e¡ect on ubiquitina-
tion. Addition of the peptide did not inhibit the hydrolysis of
£uorogenic substrate by puri¢ed proteasomes and did not a¡ect
the ubiquitination of lysozyme. An excess of the peptide failed
to compete for binding of a synthetic tetra-ubiquitin complex to
the S5a ubiquitin-binding subunit of the 19S regulator, con¢rm-
ing that the GAr does not block the access of ubiquitinated
substrates to the proteasome. Our data suggest that the GAr
may act by destabilizing the interaction of ubiquitinated sub-
strates with the proteasome and promote the premature release
of the substrate. 2 2002 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Ubiquitin/proteasome-dependent proteolysis is critically in-
volved in the regulation of many cellular processes such as the
cell cycle, di¡erentiation, transcription, antigen presentation
and the selective degradation of misfolded and damaged pro-
teins [1]. The presentation of antigenic peptides derived from
ubiquitin^proteasome-dependent degradation of viral proteins
to MHC class I restricted cytotoxic T cells is a central com-
ponent of antiviral responses [2]. It is therefore not surprising
that viruses have developed means to block proteasomal pro-
cessing in order to escape detection by the host immune sys-
tem [3^9]. One interesting example of this strategy of immu-
noescape is the Epstein^Barr virus (EBV) nuclear antigen-1
(EBNA1), an essential viral product that is required for the
maintenance and replication of EBV episomes in proliferating
virus infected cells [10,11].
EBNA1 is composed of unique N- and C-terminal domains
separated by a long internal repeat of glycine and alanine
residues only (GAr) [12]. We have previously shown that the
GAr delivers an inhibitory signal that interferes with the pro-
duction of MHC class I restricted epitopes [11]. It also acts as
a transferable element on the processing of a wide variety of
proteasomal substrates including viral and cellular proteins
[13^15]. Studies on the functional characteristics of the GAr
have shown that the inhibitory e¡ect is independent on the
site of insertion into the target protein and occurs over a wide
range of sizes of the repeat [13,14]. Of note, an eight amino
acids long repeat was su⁄cient to protect IUBK from ubiqui-
tin-dependent proteolysis [14,16]. The repeat does not act by
inducing a random structural alteration of the target protein
since chimeras containing repeats of various lengths remained
functionally active, they formed complexes with their natural
binding partners and were phosphorylated, ubiquitinated or
translocated to the appropriate cellular compartments upon
speci¢c stimulation [14,17].
The mechanism by which the GAr protects di¡erent sub-
strates from ubiquitin-dependent proteolysis is still poorly
understood. The demonstration that GAr containing protea-
somal substrates are e⁄ciently ubiquitinated in vitro [13] and
in vivo [14] suggests that the GAr a¡ects a post-ubiquitination
event. In line with this possibility, insertion of the repeat in-
hibited the interaction of ubiquitinated GAr containing IUBK
chimeras with the proteasome as detected by co-immunopre-
cipitation assays [14]. This could not be ascribed to the in-
duction of signi¢cant conformational changes since nuclear
magnetic resonance and circular dichroism studies failed to
detect changes in domain organization, folding or thermal
stability compared to wild-type IUBK. [18]. Collectively, these
¢ndings suggest that the GAr may act either directly, by dis-
turbing the interaction between the substrate and the 26S
proteasome, or indirectly, by serving as a recognition domain
for a molecular chaperone that sequesters the substrate away
from the ubiquitin/proteasome pathway.
In the present investigation we have studied the e¡ect of a
synthetic GAr polypeptide in in vitro degradation assays. We
reasoned that trans-inhibition of proteolysis by an excess of
the peptide would exclude the involvement of chaperones that
utilizes the GAr as a recognition signal for relocalization of
the substrate. We report that addition of a 20-mer GAr blocks
the degradation of a reference proteasomal substrate in a
standard rabbit reticulocyte lysate in vitro degradation assay.
The peptide did not a¡ect the enzymatic activity of the pro-
teasome nor the ubiquitination of the substrate and was un-
able to compete for binding of synthetic polyubiquitin conju-
gates to the speci¢c recognition site in the S5a subunit of the
19S regulator.
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2. Materials and methods
2.1. Reagents
Hen egg white lysozyme was purchased from Sigma. 1-Biotinamido-
4-[4P-(maleimidomethyl) cyclohexanecarboxamido]butane (Biotin-
BMCC) was from Pierce. Ubiquitin aldehyde and tetra-ubiquitin
were from A⁄niti Research Products, Exeter, UK. The proteasome
inhibitors carboxybenzyl-leucyl-leucyl-leucine vinyl sulfone (Z-L3-VS)
was a gift from H. Ploegh (Harvard Medical School, Boston, MA,
USA); carboxybenzyl-leucyl-leucyl-leucinal (MG-132) was from Pep-
tide Institute, Inc.; lactacystin was from A⁄niti. The 20-mer GA-20
(AGAGGGAGGAGAGGGAGGAG), and the 15-mers FRNL
(FRNLAYGRTCVLGKE) and LSRA (LSRAQQADAGGASGS)
oligopeptides were produced by Alta Bioscience, the University of
Birmingham, UK. Peptide stocks were kept at a concentration of
5 mg/ml in DMSO.
2.2. Labeling of lysozyme
Chicken egg white lysozyme was labeled using 125Iodine (Amersham
Pharmacia Biotech) and Chloramine T-catalyzed iodination reaction
as described previously [19]. The peak radioactive fraction (500 Wl,
with protein concentration 0.75 mg/ml) was collected and used as
substrate for in vitro degradation assays. Biotinylation was performed
using the Biotin-BMCC sulfhydryl-reactive biotinylation reagent, ac-
cording to the manufacturer’s instructions. Brie£y, 6 mg of lysozyme
in a 2.5 ml volume of PBS were incubated with 0.1 ml of 8.5 mM
Biotin-BMCC reagent in DMSO for 2 h at room temperature. The
excess of Biotin-BMCC was removed by microconcentrator (Milli-
pore) centrifugation. For in vitro degradation assays biotinylated ly-
sozyme was chloraminated in ratio 1:1 with Chloramine-T (1 mg/ml
in PBS) for 5 min and then equal volumes of 50 mM sodium bisul¢te
and 50 mM ascorbic acid were added to the reaction. The partially
denaturated lysozyme was then washed with ascorbic acid using mi-
croconcentrator centrifugation. Stocks of labeled lysozyme at a con-
centration of 0.5 mg/ml were stored at a 370‡C until use.
2.3. In vitro ubiquitination and degradation assays
Rabbit reticulocyte lysates were prepared as described previously
[20] and used as a source of proteasomes and ubiquitination enzymes.
The ubiquitination and degradation reactions were performed as de-
scribed previously [13]. Brie£y, 8 Wl of crude rabbit reticulocyte lysate
was added to a reaction mixture containing 40 mM Tris^HCl, pH 7.6,
5 mM Mg2Cl, 2 mM DTT, 0.2 mg/ml ubiquitin and either iodinated
or biotinylated protein substrate (2 Wl) in a total volume of 20 Wl. The
reactions were carried out for 2 h at 37‡C in the presence of ATP-
regenerating system (0.5 mM ATP, 10 mM phosphocreatine, 0.2 mg/
ml creatine phosphokinase). For ubiquitination assays, the reaction
was performed for 20 min at 37‡C in the presence of the isopeptidase
inhibitor, ubiquitin aldehyde at a ¢nal concentration 20 Wg/ml. The
control reactions were kept on ice. The reactions were terminated by
addition of SDS-sample bu¡er and the degradation products were
fractionated by 12% SDS^PAGE. Speci¢c bands were visualized ei-
ther by Phosphorimager (Molecular Dynamics) analysis of dried gels
for iodinated lysozyme or by NeutrAvidin, horseradish peroxidase
conjugated reagent (Pierce) and enhanced chemiluminescence (Super-
Signal West Dura extended duration substrate, Pierce) Western blots
for biotinylated lysozyme. Where indicated, the proteasome inhibitors
Z-L3-VS, MG132, lactacystin or speci¢c oligopeptides GA-20 and
FRNL were added in ubiquitination and degradation assays.
2.4. Measurement of enzymatic activity of the 20S proteasome
20S proteasomes were puri¢ed in the absence of ATP as described
previously [21]. Fluorogenic substrates succinyl-Leu-Leu-Val-Tyr-ami-
nomethylcoumarin (Suc-LLVY-AMC), Boc-Leu-Arg-Arg-aminome-
thylcoumarin (Boc-LRR-AMC) and acetyl-Tyr-Val-Ala-Asp-amino-
methylcoumarin (Ac-YVAD-AMC) were used to assay the
chymotrypsin-like, trypsin-like and caspase-like activities of the pro-
teasome, respectively, were from Sigma. Fluorogenic substrates (100
WM) were incubated for 1 h at 37‡C with puri¢ed proteasomes in
bu¡er containing 50 mM Tris^HCl, pH 7.5, 5 mM MgCl2 and
1 mM DTT in a ¢nal volume of 100 Wl. Where indicated, the protea-
somes were pre-incubated either with GA-20, FRNL and LSRA oli-
gopeptides or proteasome inhibitor Z-L3-VS for 30 min at 37‡C be-
fore substrates were added. Reactions were quenched with 1 ml of
99% ethanol and the £uorescence was determined in a £uorimeter
(Perkin-Elmer, Beacons¢eld, UK) using an excitation of 380 nm
and emission of 440 nm.
2.5. Production of a GST^S5a fusion protein and tetra-ubiquitin
binding assay
The S5a, S8 and S12 genes were ampli¢ed from Marathon-Ready
human leukocyte cDNA library (Clontech) using the sense primer: 5P-
AAAAGATCTCCATGGTGTTGGAAAGCACTA (BglII restriction
site, underlined; start codon of S5a in bold) and the antisense primer:
5P-AAAGTCGACTCACTTCTTGTCTTCCTCCTT (SalI restriction
site, underlined; stop codon in bold) for S5a, the sense primer: 5P-
TCTAAGATCTCCATGGCGCTTGACGGACCA and the antisense
primer: 5P-CCTTGTCGACTCACTTCCATAATTTCTTGA for S8,
and the sense primer 5P-AAAGGATCCTCATGCCGGAGCTGG-
CAGTGCAGAA (BamHI restriction site, underlined) and the anti-
sense primer 5P-AAAGTCGACTTACTTTTTCTCCTTTTTCTCCTC
for S12 in PCR reactions using Taq DNA polymerase (Life Technol-
ogies). The PCR products were digested with BglII (BamHI for S12)
and SalI and cloned in the BamHI/SalI sites of the pGEX-5X-1 vector
(Pharmacia Biotech) for GST-fusion protein expression. The con-
structs were veri¢ed by DNA sequencing. The fusion proteins were
expressed in Escherichia coli strain BL-21 and puri¢ed under non-
denaturating conditions according to the manufacturer’s recommen-
dations. The protein concentration was measured by the BCA assay
(Pierce) and the purity was assessed by fractionation in 10% SDS^
PAGE and Coomassie blue staining. For in vitro binding assay, 4 Wg
of GST-fusion proteins were immobilized on 10 Wl (bed volume) glu-
tathione^Sepharose 4B beads (Pharmacia Biotech). The beads were
washed two times with 1 ml ice-cold PBS bu¡er and then were incu-
bated with 2 Wg of tetra-ubiquitin for 2 h at 4‡C with or without
Fig. 1. A synthetic GAr peptide inhibits the degradation of iodi-
nated lysozyme in vitro. (A) Iodinated lysozyme was mixed with
crude rabbit reticulocyte lysate in the presence of ATP regenerating
system and the reaction was allowed to proceed for 2 h at 37‡C.
The indicated amounts of Z-L3-VS or MG-132 proteasome inhibi-
tors, the 20 amino acids long glycine^alanine peptide (GA-20) or a
15 amino acids long peptide of random sequence (FRNL) were
added to the reaction. The reaction mixture was fractionated in
12% SDS^PAGE. Control sample was kept on ice. One representa-
tive experiment out of three. (B) Densitometry analysis of the ex-
periment presented in (A). MeanUS.E.M. of three experiments.
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addition of the indicated molar concentrations of the GA-20 or
FRNL peptides. The beads were washed ¢ve times with ice-cold
PBS bu¡er, resuspended in SDS sample bu¡er and fractionated by
12% SDS^PAGE. Immunoblotting was performed with an anti-ubiq-
uitin antibody (DAKO).
3. Results
3.1. A synthetic GAr peptide blocks the ubiquitin/proteasome-
dependent degradation of iodinated and biotinylated
lysozyme
To investigate the mechanism by which the GAr inhibits the
ubiquitin/proteasome system, a synthetic 20-mer oligopeptide
containing a sequence derived from the 238 amino acid long
full length GAr of the prototype B95.8 EBNA1 protein was
added to in vitro degradation assays using as a substrate
iodinated lysozyme. The FRNL oligopeptide of random se-
quence was used as a speci¢city control (Fig. 1A). In accor-
dance with previous reports, iodinated lysozyme was e⁄-
ciently degraded in an ATP (not shown) and temperature-
dependent manner resulting in 90% decrease of the speci¢c
band detected in SDS^PAGE compared to control (Fig. 1B,
lanes 1 and 2). As expected, substrate hydrolysis was e⁄-
ciently blocked by addition of the proteasome inhibitors
Z-L3-VS and MG-132 (Fig. 1B, lanes 3 and 4), con¢rming
the involvement of the proteasome. The hydrolysis of iodi-
nated lysozyme was signi¢cantly decreased by addition of
200 or 20 WM GA-20 peptide, resulting in six- and three-
fold inhibition, respectively, (Fig. 1B, lanes 5 and 6). The
FRNL oligopeptide had no e¡ect (Fig. 1B, lane 7) suggesting
that the inhibitory e¡ect is GAr peptide-speci¢c.
In order to further analyze the mechanism of action of the
GAr we developed an e⁄cient biotinylation method for sub-
strate labeling that provides several advantages in the in vitro
assay. First, the substrate is not radioactive and the handling
is therefore easier. Second, the biotin label is very stable and
once the protein is labeled it may be stored for months or
even years without loss of activity. Most signi¢cantly, the
biotin^avidin detection method is extremely sensitive. As
shown in Fig. 2A, loading of 1 ng of biotinylated lysozyme
in SDS^PAGE was su⁄cient for a very strong signal (Fig. 2A)
while up to a 10-fold higher amount of iodinated material was
needed for detection (not shown). It is noteworthy that Chlo-
ramine T is used in the iodination reaction and this results
in partial denaturation of the substrate. We found that this
denaturation step is essential for in vitro degradation of lyso-
zyme by the ubiquitin/proteasome system since only Chlo-
ramine T-treated biotinylated lysozyme was e⁄ciently de-
graded in vitro (Fig. 2B).
Fig. 2. Partial denaturation is required for in vitro degradation of
biotinylated lysozyme. (A) The indicated amounts of biotinylated ly-
sozyme were fractionated by 12% SDS^PAGE and the protein was
blotted on nitrocellulose ¢lter and detected by NeutrAvidin. The ef-
¢ciency of detection was approximately 10-fold higher to compare
to iodination. (B) Biotinylated lysozyme was exposed to crude rab-
bit reticulocyte lysate with or without previous treatment with
Chloramine T. Only the denaturated protein was sensitive to ubiqui-
tin^proteasome-dependent degradation.
Fig. 3. The inhibition of ubiquitin^proteasome-dependent degradation by GA-20 peptide is dose dependent. (A) Biotinylated lysozyme was de-
graded in the presence of the indicated amounts of lactacystin or Z-L3-VS proteasome inhibitors, the GA-20 peptide or 15 amino acid long
peptide of random sequence (FRNL). The reaction mixture was fractionated in 12% SDS^PAGE. SDS^PAGE of one representative experiment
out of three. (B) Densitometry analysis of the experiment presented in (A). The percent of residual protein was calculated as the ratio between
the experimental sample and the control sample kept at 0‡C
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The degradation of biotinylated lysozyme was inhibited by
the GA-20 peptide in a dose-dependent manner (Fig. 3A). Of
note, the level of inhibition achieved in the presence of 200
WM peptide was comparable to that achieved in the presence
of a similar molar concentration of Z-L3-VS or 20 WM lacta-
cystine (Fig. 3B).
3.2. The GAr peptide does not a¡ect the enzymatic activity of
the proteasome
To test whether the e¡ect of the GA-20 peptide may be due
to interference with the enzymatic activity of the 20S catalyt-
ical core particle, di¡erent concentrations of the peptide were
included in enzymatic assays where the activity of semipuri¢ed
20S proteasomes was tested on £uorogenic substrates that
monitor chymotrypsin, trypsin and caspase-like activities
(not shown). While hydrolysis of the substrates was abrogated
by addition of 50 WM of peptide vinyl sulfone Z-L3-VS, the
GA-20 peptide induced some inhibition only at the highest
concentrations tested (Fig. 4), which is likely to re£ect a
non-speci¢c interference by the high concentration of peptide.
It is noteworthy that the FRNL oligopeptide could not be
used as control in this assay due to the presence of both
trypsin and chymotrypsin cleavage sites. (Data not shown).
3.3. The GAr peptide does not a¡ect ubiquitination
We have previously shown that insertion of the GAr in
proteasomal substrates did not a¡ect their ubiquitination in
vitro and in vivo [13,14]. To investigate whether this is true
also in the presence of a great excess of the GAr we asked
whether ubiquitination might be a¡ected by the GA-20 pep-
tide. Biotinylated lysozyme was incubated with crude rabbit
reticulocyte lysate in the presence of ubiquitin aldehyde that
blocks the activity of ubiquitin isopeptidases. As expected,
this resulted in a signi¢cant accumulation of high molecular
weight species corresponding to ubiquitinated lysozyme (Fig.
5). No di¡erence was observed when the GA-20 peptide was
added to the reaction, thus con¢rming that the GAr does not
interfere with the ubiquitination machinery.
3.4. The GAr peptide does not a¡ect the recognition of
polyubiquitin conjugates by the S5a subunit
In the ¢nal set of experiments we asked whether the GA-20
peptide could act by blocking the binding of ubiquitinated
proteins to the 19S regulatory particle of the proteasome.
This is a complex issue since several subunits of the 19S are
Fig. 4. The GA-20 peptide does not a¡ect the enzymatic activity of
the proteasome against £uorogenic substrates. The hydrolysis of the
£uorogenic substrates Suc-LLVY-AMC (chymotrypsin-like activity)
and Boc-Leu-Arg-Arg-aminomethylcoumarin (Boc-LRR-AMC)
(trypsin-like activity) by semipuri¢ed 20S proteasomes was tested
with or without addition of 50WM of the proteasome inhibitor
Z-L3-VS or the indicated amounts of the GA-20 peptide. The re-
sults are expressed as percent inhibition calculated as the ratio be-
tween the percent hydrolysis in the presence or absence of the indi-
cated concentrations of the proteasome inhibitor or GA-20 peptide.
The assay was calibrated in order to achieve linear dose response
conditions. Mean of two experiments.
Fig. 5. The GA-20 peptide does not prevent the ubiquitination of
biotinylated lysozyme. Biotinylated lysozyme was incubated in the
presence of crude rabbit reticulocyte lysate, ubiquitin aldehyde (20
Wg/ml), proteasome inhibitor Z-L3-VS (200 WM) and GA-20 peptide
(200 WM). The proteins were separated by 12% SDS^PAGE, trans-
ferred on to nitrocellulose membrane and detected by NeutrAvidin
and enhanced chemiluminescence Western blotting. SDS^PAGE of
one representative experiment out of three. The non-speci¢c band
indicated by an asterisk was detected only in this assay and is prob-
ably due to the presence of impurities in the original material that
was biotinylated.
Fig. 6. The GA-20 peptide does not a¡ect the binding of tetra-ubiquitin to S5a proteasome subunit in vitro. GST^S5a, GST^S8 and GST^S12
fusion proteins were immobilized on glutathione^Sepharose beads and then incubated with tetra-ubiquitin. Where indicated, increasing concen-
trations of the GA-20 peptide or the control FRNL peptide were added to the binding reaction. After extensive washing the retained proteins
were fractionated by 10% SDS^PAGE and immunoblotted with anti-Ub antibody.
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likely to interact with polyubiquitin, with various substrates
or with substrate-bound chaperones. The best characterized
interaction is that of the S5a subunit with a speci¢c domain
in polyubiquitin conjugates that contain at least four ubiquitin
moieties [22^24]. In order to investigate whether the GA-20
peptide could interfere with this binding, a GST^S5a fusion
protein was immobilized on glutathione^Sepharose beads and
then exposed to a synthetic tetra-ubiquitin multimer that
mimics the ubiquitin ladder of polyubiquitinated proteins.
GST fusions of two additional components of the 19S cap,
S8 and S12, that, on the basis of available literature, are not
expected to bind to polyubiquitin, were included as speci¢city
control. Tetra-ubiquitin bound very e⁄ciently to S5a, as ex-
pected, while there was no detectable binding to S8 or S12
(Fig. 6). The strong interaction of polyubiquitin with S5a was
not a¡ected by addition of increasing concentration of the
GA-20 peptide or the control FRNL peptide. Thus, the
GAr does not compete for interaction of ubiquitinated pro-
teins with the polyubiquitin acceptor site of the proteasome.
4. Discussion
The Gly^Ala repeat of EBNA1 is the only known protein
domain that acts as a modular inhibitor of the ubiquitin^pro-
teasome system and prevents proteolysis of a broad variety of
proteasomal substrates, independently on their proteasome
targeting signal or type of ubiquitin ligase involved in ubiq-
uitination. Although studies in model systems have revealed
some of the chemical and structural properties that are critical
for the inhibitory activity of the repeat, the mechanism of
action remains still elusive. One puzzling feature emerging
from studies where GAr containing proteins were over-ex-
pressed in living cells is that the repeat a¡ected exclusively
the degradation of the protein where it was inserted [11].
The failure to inhibit proteolysis in trans led to the hypothesis
that the repeat may alter the structure of the substrate and/or
serve as a recognition signal for chaperones that sequester the
substrate away from the proteasome. Later studies have re-
vealed that the activity of the proteasome is highly redundant
in cells, probably in response to the need to clear huge
amounts of substrates during stress responses [15]. Thus,
even when highly overexpressed, the GAr-containing proteins
may not reach the concentration required for trans inhibition
of the ubiquitin/proteasome system in vivo. In this report, we
have reinvestigated this question by testing the capacity of a
synthetic GAr peptide to interfere with the degradation of a
model substrate in vitro.
We have now shown that the GAr peptide can inhibit the
degradation of a model substrate in vitro. In accordance with
previous observations [11,13^15], the GAr did not a¡ect ubiq-
uitination of the substrate and did not alter the enzymatic
activity of puri¢ed proteasomes. These ¢ndings have at least
two important implications. First, the ¢nding that the GAr
can, under appropriate conditions, inhibit proteolysis in trans
provides conclusive evidence against its capacity to target
chaperones that sequester the substrate away from the protea-
some. If this were the case, addition of a competitor peptide
would not have e¡ected the processing of a substrate that
lacks the GAr domain. Second, our failure to detect any sig-
ni¢cant e¡ect on ubiquitination, strongly support the conclu-
sion that the GAr directly a¡ects the interaction of ubiquiti-
nated substrates with the proteasome.
Very little is known about the events that lead to recogni-
tion of ubiquitinated substrates by the proteasome, their un-
folding and tethering into the proteolytic cavity. It seems
likely that several components of the 19S regulator will con-
tribute in what is probably a tightly regulated and perfectly
timed sequence of events. Conceivably, the recognition of the
ubiquitinated substrate is the ¢rst, rate-limiting step. This is
partly achieved through recognition of conformational do-
mains in the polyubiquitin tree by the S5a subunit of the
19S cap [24]. Interestingly, the ubiquitin-interacting domain
of S5a is a hydrophobic region that bears some similarity to
the GAr [23,25]. We have shown that the GA-20 peptide does
not interfere with the binding of a synthetic tetra-ubiquitin
conjugate to a GST^S5a fusion in vitro. This implies that
the GAr does not prevent the interaction of the ubiquitinated
substrate with proteasome through competition for binding to
the ubiquitin speci¢c subunit. However, the demonstration
that deletion of the S5a subunit is not lethal in yeast [26]
suggests that other components of the 19S regulatory particle
must be involved in substrate recognition. This additional
interaction may be required to stabilize the initial binding
and retain the substrate until subsequent irreversible modi¢-
cations will take place. Conceivably, weakening of this com-
plementary anchor might result in premature release of the
substrate that, through the action of cytosolic isopeptidase
and chaperones, will be returned to the pool of cellular pro-
teins.
This attractive scenario may be di⁄cult to prove experimen-
tally for several reasons. First, the existence of a putative
complementary anchor involving direct interaction between
the proteasome and the substrate is di⁄cult to reconcile
with the huge number of broadly di¡erent substrates that
are degraded by the proteasome. Although the existence of
proteasome subunits capable of recognizing subsets of similar
substrates cannot be excluded, it is possible that interaction
may be achieved through speci¢c chaperones that escort the
ubiquitinated substrate to the proteasome. The recent demon-
stration that some ubiquitin ligases bind, directly or indirectly,
to the proteasome [27^30] suggests that the E3 themselves
may mediate this complementary anchor. If so, the GAr
may act either by preventing binding of the chaperone to
the substrate or by interfering with the interaction between
the proteasome and the E3. Second, the strict temporal
sequence of the events that led to proteolysis, including
recognition, deubiquitination and unfolding, and the in-
volvement of di¡erent partners at each step, suggest that
all these interactions must be short lived and of low a⁄nity.
If so, even a weak interference of the GAr with any of the
partners involved could have major e¡ects on the entire pro-
cess.
In conclusion, the ¢ndings reported in this paper strongly
support a model for the inhibitory activity of the GAr that
involves interference with the interaction of the ubiquitinated
substrate with the proteasome. The nature of this interaction
and the involved partners remain an important focus for fu-
ture studies.
Acknowledgements: This work was supported by grants from the
Swedish Cancer Society, the Swedish Foundation for Strategic Re-
search and the Karolinska Institutet, Stockholm, Sweden. A.L. was
partly supported by a fellowship from the Joint MSc/PhD Program of
the Medical Academy of Latvia (AML) and the Karolinska Institute
(KAMP).
FEBS 26210 19-6-02
A. Leonchiks et al./FEBS Letters 522 (2002) 93^98 97
References
[1] Hershko, A. and Ciechanover, A. (1998) Annu. Rev. Biochem.
67, 425^479.
[2] Rock, K.L. and Goldberg, A.L. (1999) Annu. Rev. Immunol. 17,
739^779.
[3] Kuhne, C. and Banks, L. (1998) J. Biol. Chem. 273, 34302^
34309.
[4] Scheiner, M., Nuber, U. and Huibregtse, J.M. (1995) Nature 373,
81^83.
[5] Hu, Z., Zhang, Z., Doo, E., Coux, O., Goldberg, A.L. and
Liang, T.J. (1999) J. Virol. 73, 7231^7240.
[6] Fischer, M., Runkel, L. and Schaller, H. (1995) Virus Genes 10,
99^102.
[7] Rousset, R., Desbois, C., Bantignies, F. and Jalinot, P. (1996)
Nature 381, 328^331.
[8] Berezutskaya, E. and Bagchi, S. (1997) J. Biol. Chem. 272,
30135^30140.
[9] Tortorella, D., Gewurz, B.E., Furman, M.H., Schust, D.J. and
Ploegh, H.L. (2000) Annu. Rev. Immunol. 18, 861^926.
[10] Yates, J.L., Warren, N. and Sugden, B. (1985) Nature 313, 812^
815.
[11] Levitskaya, J., Coram, M., Levitsky, V., Imreh, S., Steigerwald-
Mullen, P.M., Klein, G., Kurilla, M.G. and Masucci, M.G.
(1995) Nature 375, 685^688.
[12] Allday, M.J. and MacGillivray, A.J. (1985) J. Gen. Virol. 66,
1595^1600.
[13] Levitskaya, J., Sharipo, A., Leonchiks, A., Ciechanover, A. and
Masucci, M.G. (1997) Proc. Natl. Acad. Sci. USA 94, 12616^
12621.
[14] Sharipo, A., Imreh, M., Leonchiks, A., Imreh, S. and Masucci,
M.G. (1998) Nat. Med. 4, 939^944.
[15] Dantuma, N.P., Heessen, S., Lindsten, K., Jellne, M. and Ma-
succi, M.G. (2000) Proc. Natl. Acad. Sci. USA 97, 8381^8385.
[16] Sharipo, A., Imreh, M., Leonchiks, A., Branden, C. and Masuc-
ci, M.G. (2001) FEBS Lett. 499, 137^142.
[17] Heessen, S., Leonchiks, A., Issaeva, N., Sharipo, A., Selivanova,
G., Masucci, M.G. and Dantuma, N.P. (2002) Proc. Natl. Acad.
Sci. USA 99, 1532^1537.
[18] Leonchiks, A., Liepinsh, E., Barishev, M., Sharipo, A., Masucci,
M.G. and Otting, G. (1998) FEBS Lett. 440, 365^369.
[19] Heemels, M.T., Schumacher, T.N., Wonigeit, K. and Ploegh,
H.L. (1993) Science 262, 2059^2063.
[20] Shae¡er, J.R. and Cohen, R.E. (1996) Biochemistry 35, 10886^
10893.
[21] Gavioli, R., Frisan, T., Vertuani, S., Bornkamm, G.W. and Ma-
succi, M.G. (2001) Nat. Cell Biol. 3, 283^288.
[22] Beal, R.E., Toscano-Canta¡a, D., Young, P., Rechsteiner, M.
and Pickart, C.M. (1998) Biochemistry 37, 2925^2934.
[23] Young, P., Deveraux, Q., Beal, R.E., Pickart, C.M. and Re-
chsteiner, M. (1998) J. Biol. Chem. 273, 5461^5467.
[24] Thrower, J.S., Ho¡man, L., Rechsteiner, M. and Pickart, C.M.
(2000) EMBO J. 19, 94^102.
[25] Fu, H., Sadis, S., Rubin, D.M., Glickman, M., van Nocker, S.,
Finley, D. and Vierstra, R.D. (1998) J. Biol. Chem. 273, 1970^
1981.
[26] van Nocker, S., Sadis, S., Rubin, D.M., Glickman, M., Fu, H.,
Coux, O., Wefes, I., Finley, D. and Vierstra, R.D. (1996) Mol.
Cell Biol. 16, 6020^6028.
[27] Jager, S., Strayle, J., Heinemeyer, W. and Wolf, D.H. (2001)
EMBO J. 20, 4423^4431.
[28] Farras, R., Ferrando, A., Jasik, J., Kleinow, T., Okresz, L., Ti-
burcio, A., Salchert, K., del Pozo, C., Schell, J. and Koncz, C.
(2001) EMBO J. 20, 2742^2756.
[29] Xie, Y. and Varshavsky, A. (2000) Proc. Natl. Acad. Sci. USA
97, 2497^2502.
[30] Jager, S., Strayle, J., Heinemeyer, W. and Wolf, D.H. (2001)
EMBO J. 20, 4423^4431.
FEBS 26210 19-6-02
A. Leonchiks et al./FEBS Letters 522 (2002) 93^9898
